Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. - Wikidata - awgldk - TriplyDB

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.

http://www.wikidata.org/entity/Q45011636

about

Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer.Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis.Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date Therapy for metastatic melanoma: the past, present, and future.Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.Gentian violet: a 19th century drug re-emerges in the 21st century Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report.The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model.Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept Positron emission tomography imaging of vascular endothelial growth factor receptor expression with (61)Cu-labeled lysine-tagged VEGF121.Spheroid-plug model as a tool to study tumor development, angiogenesis, and heterogeneity in vivo.Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.Tanycytic VEGF-A boosts blood-hypothalamus barrier plasticity and access of metabolic signals to the arcuate nucleus in response to fasting.Efficacy of combined axitinib with dacarbazine in a B16F1 melanoma xenograft model Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis.Metastatic melanoma - a review of current and future drugs Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours.BRAF and beyond: Tailoring strategies for the individual melanoma patient Pharmacokinetic evaluation of axitinib.Advances in the management of melanoma: targeted therapy, immunotherapy and future directions.The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis.Update on the targeted therapy of melanoma.Clinical pharmacology of axitinib.Inhibition of angiogenesis for the treatment of metastatic melanoma.Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma.Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials.Angiogenesis, vasculogenic mimicry and vascular invasion in cutaneous malignant melanoma - implications for therapeutic strategies and targeted therapies.Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma.Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications.Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.A new look at drugs targeting malignant melanoma--an application for mass spectrometry imaging.Receptor tyrosine kinase inhibitors: Are they real tumor killers?

P2860

Q26741201-91D854A3-C264-4D29-897C-45BC3CD06F3E Q28728389-192A49F7-2A4F-43C2-80CC-E7C65ADE7215 Q33404877-DD2742CC-1E1C-4DD0-9C56-6CD5E3D7F9DF Q33420495-41E49A5A-5B6D-4D4E-A515-130DFAB73B91 Q33424379-628F4EB0-5EAB-4D02-A2A0-F3C80585B76B Q33887664-CA6567CA-4C88-4305-AB28-2AA4A65601BC Q34183225-7EF5B3EF-1D01-43DA-ACF9-5274C1CBAC8B Q34245458-822B1400-3B49-410D-8CED-212F6C0CDCC9 Q34377198-7B2732EC-F31F-4E78-A288-B92A338B451F Q35051078-AD82B5A8-BE70-4BC1-8BED-1D17FA86F53A Q35475284-C5DD4828-3D62-4AEF-9878-84148C243497 Q35798966-A19CB7DD-6F63-4302-88A5-121985CBAB32 Q35923178-17F3EA49-6246-4ED8-A567-CF2F2533C8A6 Q35947278-EA5091BE-9D26-4037-BC61-3C0462E19677 Q36387806-083EC463-30B7-4368-B6F7-0FD0F6CD37E2 Q36392351-F9F6458F-8283-44A3-B7FC-1DA8AAF44C1B Q36712746-831AD047-E7C7-43CB-A362-AE254297DB47 Q36746567-BE478F35-CCAD-4219-B676-6D082CB85F63 Q36828773-AF12431A-8565-43C2-B126-DE2CA6855B91 Q36876472-4F572C21-9F59-41C8-A304-4FFD062E2EA2 Q36962238-44D9838D-9ACE-41A7-866A-C1954C7D9640 Q37093432-4CEB2694-FF02-41D4-98BA-1BFCC653E135 Q37161889-6F4DD66E-6B4A-4349-AA93-FB30F6220FE0 Q37450733-43B94F53-8C8A-4722-A511-51658C6AA850 Q37594384-34E1E4D6-68F1-4396-81FE-3E131291EF69 Q37702515-A77DD745-29B1-4C95-96A8-E852C06CFE92 Q37976135-9F0A7568-859D-4A78-BD3A-451E80685A0E Q38068205-A067D253-490D-4B48-98D3-3A07379D9622 Q38076349-49EA4A30-1313-4EE8-A740-CE0D0CA8D26A Q38082713-2A148134-1AE3-4E8E-819D-DB57B6D7C6DD Q38107175-291C0393-5F28-4075-9F24-05A5E6BAE0CB Q38134302-89AE6C1B-1902-4EBC-92C6-4B6D9BBAF38F Q38163976-FCA1724C-7262-4E6E-898F-0A12AA2CE482 Q38185688-03AADE6B-136B-400C-A119-65932C109CA5 Q38186064-1CF01184-D45C-4536-BFC0-D2E579AD5EBE Q38195656-4A2D2751-B48F-4019-B414-D5A64BBC08C4 Q38196881-309BEAA6-8E42-42FD-BA46-96FBA62C3448 Q38196939-81159652-7D0D-4C64-A9F6-B6875DA65B6C Q38232032-4F315C6E-E1E1-4234-B010-95039414DB5E Q38365290-3582AD67-D9A0-4DF7-8B8F-7297797D0EA5

P2860

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.

http://www.wikidata.org/entity/Q45011636

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Multicenter, phase II study of ...... ents with metastatic melanoma.

@en

Multicenter, phase II study of ...... ents with metastatic melanoma.

@nl

type

label

Multicenter, phase II study of ...... ents with metastatic melanoma.

@en

Multicenter, phase II study of ...... ents with metastatic melanoma.

@nl

prefLabel

Multicenter, phase II study of ...... ents with metastatic melanoma.

@en

Multicenter, phase II study of ...... ents with metastatic melanoma.

@nl

P1433

Q45011636-E0F92B17-5CEF-49CE-8A5D-4118C566678D

P1476

Q45011636-7E8F12BD-33F4-4889-8032-A647D2263251

P2093

Q45011636-129BF2C8-D383-455C-A248-23B1D75A78CF

Q45011636-26F330F1-D82E-4C75-88CF-F32BAE20B0B2

Q45011636-457A1B7D-C1A2-4002-8FF0-894C7A66ED95

Q45011636-4E0AD047-6AF0-454B-BB46-9A398B0DE57E

Q45011636-69F0B938-62AF-460C-9D00-FF38F214A927

Q45011636-86553BB8-F9E2-4E27-8629-C73ED942F3ED

Q45011636-8BDBFED0-4192-46B4-9FD8-0AE82C278F82

Q45011636-BC999F32-2EF8-4CCD-9985-3A65061FFD06

Q45011636-BD09E11C-AAE5-47A3-9F32-2B23047BCF12

Q45011636-D53ECE4A-DBE1-4C7B-8B7C-47C89550B2A5

P304

Q45011636-D0F80F09-DBD1-4D29-B51E-6CB836F69A91

P31

Q45011636-035CA24E-0A86-4355-ABEF-F717F795B768

P356

Q45011636-6165B06C-08A3-4341-AC99-AEFC93064101

P407

Q45011636-0355D1DA-E41C-4F17-B35B-0678AB3A863F

P433

Q45011636-981BCCF8-66D8-48EA-8229-59FD6F36938D

P478

Q45011636-FE27392E-17BF-40D1-B96E-8B5BC0317256

P50

Q45011636-0269E0A6-B9C8-466E-BF74-3F6E3291A478

P577

Q45011636-214BA950-7A09-430B-A4DB-69996B841A3C

P5875

Q45011636-5E743084-D759-40B7-AF49-8093F8D70634

P698

Q45011636-AE772108-6FD8-4F26-8FD9-7AA769920B7D

P921

Q45011636-06C1061B-F343-44E2-84DD-2DD5CF23F70A

Q45011636-71EAD018-63CB-443C-BEF6-DD4CB780186B

P356

1078-0432.CCR-11-0534

P1433

Clinical Cancer Research

P1476

Multicenter, phase II study of ...... ents with metastatic melanoma.

@en

P2093

Andreas G Niethammer

http://www.w3.org/2001/XMLSchema#string

Brad Rosbrook

http://www.w3.org/2001/XMLSchema#string

Charles K Brown

http://www.w3.org/2001/XMLSchema#string

David McDermott

http://www.w3.org/2001/XMLSchema#string

David R Shalinsky

http://www.w3.org/2001/XMLSchema#string

Jean-Baptiste Meric

http://www.w3.org/2001/XMLSchema#string

John Fruehauf

http://www.w3.org/2001/XMLSchema#string

Jose Lutzky

http://www.w3.org/2001/XMLSchema#string

Katherine F Liau

http://www.w3.org/2001/XMLSchema#string

Sinil Kim

http://www.w3.org/2001/XMLSchema#string

P304

7462-7469

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-11-0534

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51696605

http://www.w3.org/2001/XMLSchema#string

P698

21976544

http://www.w3.org/2001/XMLSchema#string

P921